All In Biotech

Drug Trial Radar · NCT05953506

Phase 1a Study in Healthy Participants

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of HS-10506 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Jul 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

52

Planned (sponsor's estimate)

Start

Jul 17, 2023

Primary completion

Dec 24, 2023

Study completion Dec 24, 2023

Sponsor

Sponsor type
Industry
First posted
Jul 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral HS-10506 in Chinese Healthy Subjects.

Conditions

  • Healthy

Interventions

  • HS-10506Drug

    HS-10506 will be administered orally once on Day 1.

  • HS-10506 PlaceboDrug

    Matching placebo will be administered orally once on Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events (AEs), serious adverse events (SAEs) and adverse events leading to discontinuation from the study, and their correlation with the investigational drugTime frame: Screening until Trail phase (up to 5 weeks)
  2. Number of participants with clinically significant change from baseline in vital signsTime frame: From baseline to Day 3
  3. Number of participants with clinically significant abnormalities in physical examinationTime frame: From baseline to Day 3
  4. Changes in 12-lead electrocardiogram from before to after dosingTime frame: From baseline to Day 3
  5. Change in Stanford Sleepiness Scale score from before to after dosingTime frame: From baseline to 4 hours after dosing

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.